Similar articles

• More about orlistat.

  Lucas KH, Kaplan-Machlis B. Lucas KH, et al. Pharmacotherapy. 2000 Jul;20(7):872-3. doi: 10.1592/phco.20.9.872.35203. Pharmacotherapy. 2000. PMID: 10907983 No abstract available.
• Orlistat half the dose without a prescription: new status. In excess body weight: often uncomfortable and don't expect miracles. Frequent gastrointestinal disturbances for a weight loss of a few kilos. Better to encourage dietary measures, exercise and individualised support.

  [No authors listed] [No authors listed] Prescrire Int. 2009 Jun;18(101):101. Prescrire Int. 2009. PMID: 19637413 No abstract available.
• Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.

  Micić D, Ivković-Lazar T, Dragojević R, Jorga J, Stokić E, Hajduković Z. Micić D, et al. Med Pregl. 1999 Sep-Oct;52(9-10):323-33. Med Pregl. 1999. PMID: 10624380 Clinical Trial. Croatian, English.
• Lipid metabolic enzymes: emerging drug targets for the treatment of obesity.

  Shi Y, Burn P. Shi Y, et al. Nat Rev Drug Discov. 2004 Aug;3(8):695-710. doi: 10.1038/nrd1469. Nat Rev Drug Discov. 2004. PMID: 15286736 Review. No abstract available.
• Orlistat: its current status as an anti-obesity drug.

  Ballinger A, Peikin SR. Ballinger A, et al. Eur J Pharmacol. 2002 Apr 12;440(2-3):109-17. doi: 10.1016/s0014-2999(02)01422-x. Eur J Pharmacol. 2002. PMID: 12007529 Review.